Research into the molecular underpinnings governing breast tumor progression has yielded considerable clinical benefits for HER2-positive breast cancer patients; most notably, the introduction of HER2-targeted therapies that has drastically improved disease outcome30. The gene discussed is ERBB2; the disease is breast carcinoma.